New possibilities for the therapy of secondary progressive multiple sclerosis
Patients with multiple sclerosis (MS) are at high risk for transition to secondary progressive MS (SPMS). To date, there has not been a sufficiently effective therapy for SPMS. Siponimod is a selective sphingosine-1-phosphate types 1 and 5 receptor modulator that has been shown to be more effective...
Main Authors: | A. M. Petrov, E. V. Ivashkova, I. D. Stolyarov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2019-12-01
|
Series: | Неврология, нейропсихиатрия, психосоматика |
Subjects: | |
Online Access: | https://nnp.ima-press.net/nnp/article/view/1221 |
Similar Items
-
New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
by: D. S. Kasatkin, et al.
Published: (2021-02-01) -
The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report
by: Denis S. Korobko, et al.
Published: (2023-05-01) -
Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
by: Sabsabi S, et al.
Published: (2022-05-01) -
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
by: Gajofatto A
Published: (2017-11-01) -
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
by: Liesa Regner-Nelke, et al.
Published: (2022-11-01)